Overview

Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19

Status:
Completed

Trial end date:
2021-12-30

Target enrollment:

Participant gender:

Summary

This is open-labe randomized multicenter comparative Phase III study conducted in 7 medical facilities. The objective of the study is to assess the efficacy and safety of Favipiravir for parenteral administration compared with the Standard of care (SOC) in hospitalized patients with moderate COVID-19 pneumonia.

Phase:

Phase 3

Details

Lead Sponsor:

Promomed, LLC

Collaborator:

Solyur Pharmaceuticals Group

Treatments:

Favipiravir
Remdesivir